[News Brief] NeuroSense Reports Phase 2 Biomarker Findings for PrimeC
[News Brief] NeuroSense Reports Phase 2 Biomarker Findings for PrimeC NeuroSense Therapeutics has reported biomarker findings from its Phase 2…
Asia PR
[News Brief] Nippon Shinyaku Signs Option Agreement with Elixirgen
Nippon Shinyaku has entered into an option agreement with Elixirgen Therapeutics under which it may obtain exclusive worldwide rights to…
[News Brief] Zydus Lifesciences and Sunshine Healthcare Form Sri Lanka Joint Venture
Zydus Lifesciences and Sunshine Healthcare have announced a joint venture to establish a pharmaceutical manufacturing facility in Sri Lanka. This…
[News Brief] Chime Biologics Expands Manufacturing Capacity with Cytiva Partnership
Chime Biologics has inaugurated its GMP-2 manufacturing facility in Wuhan, China, as part of its ongoing collaboration with life sciences…
[News Brief] SK Biopharmaceuticals Collaborates with Insilico Medicine for AI Drug Discovery
SK Biopharmaceuticals and Insilico Medicine have entered a research and development collaboration to discover drug candidates for neuroimmune disorders of…
[News Brief] SystImmune and Biokin Secure China Approval for Iza-bren
SystImmune and Sichuan Biokin Pharmaceutical have received regulatory approval in China for iza-bren (BL-B01D1) to treat recurrent or metastatic nasopharyngeal…
[News Brief] Axcelead DDP Joins Eli Lilly TuneLab Collaboration
Axcelead Drug Discovery Partners (DDP), Inc. has entered a collaboration with Lilly TuneLab, an artificial intelligence and machine learning drug…
[News Brief] Haisco Pharma and Eli Lilly Sign Research Collaboration
China-based Haisco Pharmaceutical Group has entered a licensing and research collaboration with Eli Lilly and Company to discover and develop…
[News Brief] Daewoong Pharma Partners for Dupilumab Biosimilar Development
South Korea-based Daewoong Pharmaceutical has partnered with China-based Chime Biologics to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent.…
[News Brief] PharmaEssentia Receives Taiwan Approval for Besremi in ET
PharmaEssentia Corporation has received approval from Taiwan’s Ministry of Health and Welfare for Besremi (ropeginterferon alfa-2b) for the treatment of…